Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. To aid in the development process, the Company incorporates its CNSProfile™, a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases

Company Growth (employees)
Type
Public
HQ
New York, US
Size (employees)
41 (est)
Intra-Cellular Therapies is headquartered in New York, US

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, US (HQ)
3960 Broadway

Intra-Cellular Therapies Financials and Metrics

Intra-Cellular Therapies Financials

Intra-Cellular Therapies's revenue was reported to be $330.7 k in FY, 2016
USD

Revenue (Q2, 2017)

114.7 k

Net income (Q2, 2017)

(17.8 m)

EBIT (Q2, 2017)

(18.6 m)

Market capitalization (08-Dec-2017)

651.8 m

Cash (30-Jun-2017)

29.6 m
Intra-Cellular Therapies's current market capitalization is $651.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.7 m577.3 k91.4 k330.7 k

Revenue growth, %

(79%)(84%)262%

R&D expense

21.2 m87.7 m93.8 m

General and administrative expense

10.3 m18.2 m24.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

668 k167.8 k219.2 k124.4 k3.3 k57.4 k124.4 k3.3 k228.4 k4.4 k95.3 k114.7 k

R&D expense

4.2 m2.8 m2.7 m4 m18.6 m17.8 m28.5 m23.4 m25.3 m23.9 m21.5 m12.5 m

General and administrative expense

1.3 m1.9 m2.1 m2.6 m3.8 m4 m3.9 m5.1 m6.5 m6.3 m6.3 m6.3 m

Operating expense total

5.5 m4.7 m4.8 m6.6 m22.4 m21.7 m32.3 m28.5 m31.8 m30.2 m27.8 m18.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

35.2 m61.3 m47.2 m48.6 m

Accounts Receivable

336.3 k51.6 k30.7 k94.3 k

Inventories

762.2 k1.3 m8 m4 m

Current Assets

38.2 m131 m483.3 m388.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

44.1 m143.6 m91.1 m68.9 m100.8 m71.4 m332.8 m37.2 m52 m200.4 m23.6 m29.6 m

Accounts Receivable

251.3 k167.8 k219.2 k124.4 k3.3 k9.1 k51.6 k98.2 k1.3 k68.2 k61.9 k

Current Assets

47.1 m146.4 m141.2 m137.5 m236.5 m212.6 m512.3 m462.9 m446.8 m541.8 m371.6 m348.8 m

PP&E

75.7 k65.1 k63.9 k57.4 k559.7 k722.1 k785.5 k731.4 k718.7 k677.7 k605.7 k628.9 k
USDFY, 2014FY, 2015FY, 2016

Net Income

(30.7 m)(104.8 m)(116.4 m)

Depreciation and Amortization

25.5 k139.6 k196.9 k

Accounts Receivable

284.7 k20.9 k(63.7 k)

Accounts Payable

(1.3 m)(419.9 k)2.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.9 m)(4.5 m)(4.5 m)(6.4 m)(22.3 m)(21.5 m)(32.2 m)(27.8 m)(30.8 m)(30.3 m)(26.9 m)

Accounts Receivable

219.2 k124.4 k3.3 k9.1 k51.6 k98.2 k1.3 k68.2 k

Accounts Payable

415.8 k503.9 k4.6 m4.9 m705 k2 m3.9 m5.4 m7.2 m
Y, 2017

Financial Leverage

1 x
Show all financial metrics

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Show all operating metrics

Intra-Cellular Therapies Market Value History

Intra-Cellular Therapies Revenue Breakdown

Intra-Cellular Therapies's Web-traffic and Trends

Intra-Cellular Therapies Company Life and Culture

You may also be interested in